retatrutide blindness and Thyroid Cancer: Why the Warning Exists Obesity Treatment Solution: Exploring the

The phase 2 signal that put retatrutide on the map The pivotal early evidence is the phase 2 trial published in the New England Journal of Medicine in 2023, which randomized 338 adults with obesity to escalating retatrutide doses or placebo over 48 weeks

If it remains cloudy after 10 minutes of gentle swirling, something is wrong

The data shows that 18% of Black adults have taken these medications, making them more likely to have used them than White adults (10%), and Hispanic adults (13%)

The qualifying comorbidities deserve attention because many people have them without realizing it

Enhanced GIP secretion in obesity is associated with biochemical alteration and miRNA contribution to the development of liver steatosis

Tyna Moore | SHE MD for Dr